Clinical trial · Observational
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
A Multi-center Study on Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy. The main question it aims to answer is: • Does amide proton transfer-weighted imaging predict the cancer response before surgery? Participants will underwent amide proton transfer-weighted imaging as part of their regular MRI examination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- the area under curve (AUC) of receiver operating characteristic (ROC) curves of models in prediction tumor response
- timeFrame
- From date of baseline MRI to date of preoperative MRI，within 12 months
Secondary outcomes (6)
- measure
- the specificity of models in prediction tumor response
- timeFrame
- From date of baseline MRI to date of preoperative MRI，within 12 months
- measure
- the sensitivity of models in prediction tumor response
- timeFrame
- From date of baseline MRI to date of preoperative MRI，within 12 months
- measure
- the positive predictive value of models in prediction tumor response
- timeFrame
- From date of baseline MRI to date of preoperative MRI，within 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Locally advanced rectal cancer(cT3-4, or cN+), resectable, histologically confirmed rectal adenocarcinoma * Received neoadjuvant therapy before surgery * Complete radical resection of rectal cancer and postoperative pathological examination * Informed consent and signed the informed consent form Exclusion Criteria: * Poor image quality, such as severe artifacts * Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment * The interval between preoperative MRI and surgery was more than 2 weeks * Prior treatment for rectal cancer * History of other malignant tumors * Patients who cannot undergo MRI examination due to contraindications or relative contraindications * Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
References
Publications (0)
Data not yet available